Respiratory syncytial virus-associated hospitalization rates in high-risk populations: an observational comparative cohort analysis
- 143 Downloads
Compliance with ethical standards
The study was approved by the local ethic committee (No. 28-383 ex 15/16).
Conflicts of interest
BR received honoraria for oral lectures form Abbvie Austria and Germania Pharmaceuticals. The other authors reported none.
Research involving human participants and/or animals
Yes, infants and children.
Not applicable due to the retrospective study design.
- 1.Shi T, McAllister DA, O'Brien KL et al (2017) RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390:946–948CrossRefGoogle Scholar
- 2.Resch B, Bramreiter VS, Kurath-Koller S, Freidl T, Urlesberger B (2017) Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis. Eur J Clin Microbiol Infect Dis 36:1057–1062CrossRefGoogle Scholar
- 5.American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134:e620–e638CrossRefGoogle Scholar